Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Completed · Phase 2

Conditions studied: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients who have recurrent or persistent ovarian, fallopian tube, or peritoneal cancer.

Key facts

Study ID

NCT00019552

Run by

National Cancer Institute (NCI)

Starts

1998-09-01

Expected to finish

2004-04-01

Last updated by the study team

2013-06-20

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Medicine Branch — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.